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a b s t r a c t
Reactive oxygen species (ROS) play a central role in estrogen deﬁciency-induced bone loss. We previously
identiﬁed and characterized a novel member of the Peroxiredoxin (PRX) like 2 family that we called
PAMM: Peroxiredoxin Activated in M-CSF stimulated Monocytes, a redox regulatory protein that mod-
ulates osteoclast differentiation in vitro. In this study, we report increased PAMM expression in
H2O2-treated cells and in bones from ovariectomized (OVX) mice 4 weeks after surgery, models for
oxidative stress in vitro and in vivo, respectively. We also detected increased PAMM abundance and
phosphorylated Akt in OVX mice treated with estrogen. In addition, Wortmannin, a speciﬁc PI3Kinase
inhibitor and Rapamycin, an inhibitor of the PI3Kinase/Akt pathway, blocked Akt phosphorylation and
stimulation of PAMM expression by M-CSF. These results indicate that M-CSF-induced PAMM expression
is mediated by Akt phosphorylation. Our data also suggest that estrogen-induced PAMM expression is
mediated by phosphorylation of Akt. These ﬁndings point to PAMM as a potential candidate for Akt-
mediated protection against oxidative stress.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone homeostasis is inﬂuenced by decreases in defenses
against oxidative stress as well as increases in the production of
reactive oxygen species (ROS) [1]. At the cellular level, defects in
bone remodeling caused by oxidative stress are associated with
decreased osteoblast and osteoclast numbers and decreased bone
formation rate as well as increased osteoblast and osteocyte
apoptosis [2]. Aging and loss of sex steroids also result in increased
oxidative stress as reﬂected by an increase in the levels of reactive
oxygen species, and decreased activity of glutathione reductase—
an enzyme that catalyzes the reduction of glutathione disulﬁde
(GSSG) to glutathione (GSH) [3–5]. Lean et al. demonstrated that
estrogen deﬁciency contributes to bone loss by lowering thiol
antioxidants in osteoclasts [6]. Estrogen, on the other hand, can
exert beneﬁcial effects in other tissues by suppressing the gen-
eration of ROS [7]. The same changes in oxidative stress can be
acutely reproduced by ovariectomy in female rats [8]. For instance,
the levels of lipid peroxidation (LPO) and hydrogen peroxide
(H2O2) were increased and enzymatic antioxidants including su-
peroxide dismutase (SOD), glutathione peroxidase (GPx), and
glutathione S transferase (GST) were decreased in ovariectomized
animals when compared to sham-operated control rats [9]. Ovar-
iectomy not only causes an increase in the levels of ROS, but also a
reduction in the levels of the enzymes that regenerate the reduced
forms of glutathione and thioredoxin in bone marrow [6]. More-
over, levels of both antioxidants as well as their regenerative en-
zymes are rapidly normalized by treatment with 17-β estradiol
[10]. Finally, treatment with antioxidants can prevent estrogen-
deﬁciency bone loss while drugs that reduce thiol antioxidants
cause bone loss [10]. Taken together, these observations show that
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estrogen deﬁciency causes bone loss, at least in part, by lowering
antioxidant levels in bone. The presence of estrogen, on the other
hand, may prevent bone loss by enhancing bone antioxidant de-
fenses. López-Grueso et al. provided evidence that estrogen re-
placement therapy (ERT) after ovariectomy in animals can prevent
oxidative stress and metabolic alterations [11].
We cloned and characterized a novel antioxidant protein: Per-
oxiredoxin Activated in M-CSF stimulated Monocytes (PAMM)
[12]. Expression of PAMM is increased in CD14þ monocytes sti-
mulated with M-CSF (Macrophage colony-stimulating factor) and
decreases as M-CSF – stimulated cells undergo RANKL (Receptor
activator of nuclear factor kappa-B- ligand) – dependent osteoclast
differentiation. PAMM has a CXXC motif, which is essential for its
redox functions. It is expressed in bone, brain, liver, and kidney.
Our previous studies showed that expression of wild-type PAMM
in cells resulted in an increased GSH/GSSG ratio and also protected
cells from hydrogen peroxide (H2O2)-induced oxidative stress,
indicating that PAMM has antioxidant activity. In addition, PAMM
overexpression inhibited RANKL-induced osteoclast formation in
vitro [12]. ROS stimulate osteoclast differentiation and function
whereas free radical scavengers and antioxidants have the oppo-
site effect. PAMM regulates osteoclast formation and activity via
modulation of ROS production. These ﬁndings provided evidence
that PAMM is a redox regulatory protein that modulates osteoclast
differentiation in vitro, and also support a novel paradigm in which
estrogen deﬁciency results in modiﬁed expression of PAMM in
osteoclast precursors, allowing an increase in ROS, which ulti-
mately leads to increased osteoclast formation and bone
resorption.
In this study we examined the role of PAMM in ovariectomy-
induced bone loss. We sought to determine if oxidative stress in-
duces the redox-regulating activity of PAMM following ovar-
iectomy and in an established in vitro model of oxidative stress.
We also assessed the impact of estrogen treatment on PAMM ex-
pression following ovariectomy.
2. Materials and methods
2.1. Reagents
Antibodies against β-actin (no. 4967), Phospho-Akt (Ser473)
(no.9271) were purchased from Cell Signaling Technology, Inc.
(Danvers, MA). Anti-C10orf58 (PAMM) antibody (HPA009025),
17β-estradiol (E2) (E8515), corn oil (C8267), H2O2 (H1009).
Wortmannin (W1628) and Rapamycin (R8781) were purchased
from Sigma-Aldrich Inc. (St. Louis, MO). The high afﬁnity estrogen
receptor antagonist ICI 182,780 was purchased from TOCRIS
Bioscience (Minneapolis, MN-Cat no. 1047).
2.2. Mice and ovariectomy
All procedures were approved by the Forsyth Institute IACUC.
Twelve-weeks-old female Swiss Webster mice were purchased
from Charles River Laboratories (Wilmington, MA). Bilateral ovar-
iectomy (OVX, n¼12) was performed under general anesthesia
(150 mg/kg Ketamine combined with 10 mg/kg Xylazine). Sham
ovariectomy (Sham, n¼12) was similarly performed but with ex-
ternalization and replacement of the ovaries. Beginning one day
after surgery OVX animals were injected subcutaneously with
vehicle (corn oil, C8267, Sigma-Aldrich, n¼6) or with replacement
doses of E2 (E8515, Sigma-Aldrich, 30 ng/g/day, n¼6) once daily
for four weeks. Sham-operated animals received daily sub-
cutaneous injections of vehicle for four weeks. Body weight was
recorded weekly for all groups. For each animal the right femur
was ﬁxed in 4% paraformaldehyde and prepared for histological
analysis and the left distal femur was used to obtain protein ly-
sates for GSH/GSSG ratio measurement and western blot analysis
as described below.
2.3. In vivo assessment of bone mineral density (BMD)
Dual Energy X-ray Absorptiometry (DXA) scanning was per-
formed using a Lunar PIXImus Scanner (Lunar PIXImus2, software
version 1.4X) immediately prior to surgery (12 weeks of age) and
4 weeks after OVX/Sham. Total BMD (excluding the head) and
distal femur BMD were measured. For this, mice were positioned
on their abdomens with the hindlimb externally rotated. The hip
and knee were ﬂexed to 110° with the ankle in neutral position. A
region of interest (1617 pixels) at the distal femoral metaphysis
was chosen for analysis.
2.4. Cell culture
Human peripheral blood mononuclear cells (PBMCs) were
isolated from PBS-diluted blood (1/1, vol/vol) by centrifugation on
a Histopaque-1077 (Sigma-Aldrich) density gradient. CD14þ se-
lection was performed by using the Human CD14 Selection Cock-
tail (StemCell Technologies, catalog no. 18058). CD14þ PBMCs
were cultured for 4 days in α-MEM/10% FBS supplemented with
150 ng/ml human M-CSF (PeproTech Inc.) with or without 100 nM
Wortmannin [13] or Rapamycin [14]. For certain experiments cells
were incubated for 20 minutes with hydrogen peroxide (H2O2) at
the indicated concentrations. In the estrogen replacement ex-
periments, estrogen was stripped from the FBS by incubation
twice in 0.25% dextran-coated charcoal (Sigma-Aldrich, St. Louis,
MO) for 30 min at 45 °C. E2 (1 nM) and/or ICI 182,780 (100 nM) [6]
were added for estrogen replacement or estrogen inhibition,
respectively.
2.5. Real-time PCR analysis
Total RNA was extracted from cells and tissues using TRIAZOL
(Invitrogen). For RT-PCR, 2 μg of RNA was reverse transcribed into
cDNA with SuperScript II (Invitrogen, no. 18064-022). Real-time
reverse transcription polymerase chain reaction was conducted
with iQ™ SYBR
s
Green supermix (Bio Rad, Hercules, CA, USA) in a
20 μl reaction volume containing 1 μl of a 1 μl of ﬁrst-strand re-
action product and 1 μl of a 500 nM gene-speciﬁc upstream and
downstream primer mix. Ampliﬁcation and analysis of cDNA
fragments was performed using a CFX Connect™ Real-Time PCR
Detection System (Bio Rad, Hercules, CA, USA). Cycling conditions
were as follows: initial denaturation at 95 °C for 10 min, followed
by 40 cycles consisting of a 15 s denaturation interval at 95 °C, and
a 1 min annealing and extension interval at 60 °C. Ampliﬁcation of
human GAPDH mRNA, the housekeeping gene, was used as an
endogenous control to normalize expression results. Levels of
mRNA expression were measured as threshold levels (Ct) and
normalized with the individual GAPDH control Ct values. PAMM
and Nrf2 mRNA abundance were presented as relative quantiﬁ-
cation (RQ). The primer sequences were as follows: human pamm
(C10orf58) sense, 5’-ATA GAC CTG AAA ACA CTG GA-3’, and anti-
sense, 5’-GCA GCT TCC TCT CGA CAG AG-3’; human Nrf2 sense, 5′-
GAG AGC CCA GTC TTC ATT GC-3′, and antisense, 5′-TGC TCA ATG
TCC TGT TGC AT-3′; human GAPDH, sense, 5’-AAT CCC ATC ACC
ATC TTC CA-3’, and antisense, 5’-TGG ACT CCA CGA CGT ACT CA-3’.
2.6. Western blot analysis
The left distal femur of OVX and SHAM mice was resected, ﬂash
frozen in liquid nitrogen, and homogenized by hand in Novex
s
Tris–Glycine SDS Sample Buffer (Invitrogen). Cell protein lysates
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were generated by resuspending cells in the sample buffer.
Equivalent amounts of protein were loaded onto Novex Tris–Gly-
cine SDS gels (Invitrogen), electrophoresed, and transferred to
nylon membranes. After blocking, membranes were incubated
with the indicated primary antibodies overnight at 4 °C, washed in
TBST buffer to remove unbound antibody, and incubated with
secondary antibody for 1 h at room temperature. Chemilumines-
cent signal was detected with LUMIGLO reagents A and B (Cell
Signaling Technology; Danvers, MA; no. 7003) and blots were then
exposed to X-ray ﬁlm.
2.7. Histology and TRAP staining
Femurs were ﬁxed in cold 4% paraformaldehyde, decalciﬁed in
cold 14% EDTA, embedded in parafﬁn, sectioned at 5 μm and
placed on charged slides (Manco Inc., Avon, OH). Osteoclast ac-
tivity was detected by tartrate-resistant acid phosphatase (TRAP)
staining. Slides were deparafﬁnized and rehydrated through gra-
ded ethanol to distilled water. TRAP solution (0.1 M acetic acid
buffer solution; naphthol AS-MX phosphate; fast red Violet LB salt;
N,N-dimethylformamide; Sigma-Aldrich Inc.) was applied and the
sections were incubated at 37 °C for 30 min or until the control
was developed. The slides were then rinsed in distilled water,
counterstained with 0.02% Fast Green for 30 s, rinsed with water,
dehydrated through graded alcohols, and mounted. Images were
acquired with a LEICA DMLS optical microscope equipped with a
LEICA DC 100 digital imaging system.
2.8. Immunohistochemistry
Immunohistochemistry was performed on deparafﬁnized bone
sections according to standard protocols. Brieﬂy, sections were
incubated with primary antibodies at the indicated dilutions in a
humidiﬁed chamber overnight at 48 °C. The following day, the
slides were washed 310 min in 1 PBSþ0.1% (vol/vol) Tween-
20. Sections were then incubated for 1 h at room temperature with
the biotinylated secondary antibody (100 μ/section, diluted 1:250
to 1:750 in blocking buffer) in a humidiﬁed chamber. Finally, slides
were washed 310 min in 1 PBS and incubated with one drop
of ABC (Ready-to-use Vectastain ABC Kit, Vector Laboratories, Inc.,
Burlingame, CA), incubated for 30 min at room temperature, wa-
shed 35 min in 1 PBS, and incubated for 2–10 min with DAB
solution until signal developed. Images were acquired with a
LEICA DMLS optical microscope equipped with a LEICA DC 100
digital imaging system.
2.9. Measurement of GSH/GSSG ratio
The GSH/GSSG ratio was measured with the glutathione re-
ductase/5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) assay kit
(BIOXYTECHR GSH/GSSG-412TM, Catalog number 21040, OXIS In-
ternational, Beverly Hills, CA) from bone protein lysates according
to the manufacturer's instructions. Brieﬂy, total glutathione (GSHt)
and GSSG concentrations were derived from GSH and GSSG
standard curves and converted to nmol/mg of protein. Reduced
GSH concentrations were found by subtracting GSSG from total
glutathione. Finally, the GSH/GSSG ratio was calculated by dividing
the difference between total glutathione and GSSG concentrations
by the GSSG concentration (ratio¼GSHt–2 (GSSG) / GSSG) [15].
2.10. Statistical analysis
Data are presented as means plus or minus SDs from at least
three independent experiments. Statistical signiﬁcance was de-
termined by using one-way analysis of variance (ANOVA) followed
by the Student t test (*po0.05; **po0.01).
3. Results
3.1. Ovariectomy increases PAMM abundance and Akt phosphor-
ylation in Bone
Sham animals were administered vehicle. Body weight was
recorded weekly for all groups. Body composition and bone mi-
neral density (BMD) were monitored to conﬁrm effective ovar-
iectomy (OVX) and E2 replacement therapy. Uterine weight was
recorded at the time of sacriﬁce for all animals. All animals gained
weight similarly during the 4-week treatment period (Table 1) and
there were no signiﬁcant differences in weight gain based on ex-
perimental group. The mean uterine weight in the OVX/Vehicle
group was signiﬁcantly lower (po0.01) than the other groups
4 weeks after surgery (Table 1).
Distal femur bone mineral density (BMD) and whole body BMD
(excluding the head) were assessed in all groups immediately
prior to OVX/Sham and 4 weeks after OVX/Sham. There were no
signiﬁcant differences in baseline distal femur or total body BMD
between the groups (p40.05). Over the 4-week period, distal fe-
mur BMD increased signiﬁcantly in the OVX/E2 and the Sham/
Vehicle groups (70.5% and 79%, respectively) while distal femur
BMD decreased signiﬁcantly in the OVX/Vehicle group (9.7%). Si-
milarly, there was no detectable difference in whole body BMD in
the OVX/E2 and the Sham/Vehicle groups while there was a sig-
niﬁcant decline in the OVX/Vehicle group. As a result, both distal
femur and total body BMD were signiﬁcantly lower in the OVX/
Vehicle group (0.068 g/cm2 and 0.060 g/cm2, respectively) com-
pared to the OVX/E2 (0.125 g/cm2 and 0.065 g/cm2) and Sham/
Vehicle group (0.134 g/cm2 and 0.065 g/cm2) after 4 weeks of
treatment (**po0.01) (Fig. 1A). TRAP staining was performed of
sections through the distal femur and osteoclasts were quantiﬁed
as the number of TRAP positive cells per high-powered ﬁeld
(Fig. 1B). There were signiﬁcantly fewer osteoclasts in the OVX/E2
and SHAM/Vehicle groups compared to the OVX/Vehicle group
(**po0.01, Fig. 1C) conﬁrming that estrogen replacement in-
hibited ovariectomy-induced osteoclast differentiation. Moreover,
decreased GSH(t) and GSH/GSSG ratio were detected in the OVX/
Vehicle group (po0.05, Fig. 1D), conﬁrming oxidative stress in
ovariectomized mice.
Activation of the PI3K/Akt/NF-κB signaling pathway is essential
for osteoclast differentiation from monocytic precursors, osteo-
clast proliferation, osteoclast survival, and osteoclastic bone re-
sorbing activity [12,13,16]. Akt also provides a survival signal that
protects cells from apoptosis induced by growth factor withdrawal
and oxidative stress [14]. We hypothesized that ovariectomy
would result in both Akt activation and increased PAMM expres-
sion in bone. We therefore determined Akt activation in bone by
assessing Ser 473 phosphorylation status by western blot analysis.
We detected increased Akt phosphorylation in protein lysates from
the distal femur in the OVX/Vehicle and OVX/E2 groups compared
to the Sham/Vehicle group (po0.05). Similarly, we found sig-
niﬁcantly increased PAMM protein expression in the OVX/Vehicle
and OVX/E2 groups compared to the Sham/Vehicle group
(po0.05) (Fig. 2A and B). Expression of PAMM at the distal femur
was also detected by immunohistochemistry 4 weeks after OVX or
Sham-operated mice (Fig. 2C).
3.2. M-CSF stimulation of PAMM expression requires Akt
phosphorylation
We have previously shown that M-CSF induces PAMM ex-
pression in cultured CD14þ peripheral blood mononuclear cells
(PBMCs) [12]. We next determined if M-CSF stimulation of PAMM
expression required Akt phosphorylation, which requires PI3Ki-
nase activity. We stimulated human CD14þ PBMCs with M-CSF
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and determined PAMM abundance and phosphorylated Akt in the
presence of Wortmannin or Rapamycin. Wortmannin is a speciﬁc
PI3Kinase inhibitor and Rapamycin is an inhibitor of the Akt/mTOR
pathway, that acts downstream of Akt. We found that both
Wortmannin and Rapamycin blocked M-CSF induced PAMM ex-
pression via inhibited phosphorylation of Akt (Fig. 3).
3.3. Estrogen stimulates M-CSF induced PAMM Expression in
preosteoclasts
We then determined if estrogen was required for M-CSF in-
duced PAMM expression. We cultured human CD14þ PBMCs for
4 days in α-MEM/10% charcoal stripped FBS, 150 ng/mL human
M-CSF (PeproTech Inc.) and E2 with/without ICI 182,780, an es-
trogen antagonist. RT-PCR analysis of RNA isolated from the cells
demonstrated that estrogen increased pamm gene abundance
while ICI 182,780 decreased it (Fig. 4A). Western blot analysis of
protein extracts conﬁrmed these results (Fig. 4B).
Table 1
Body weight and uterine weight (Grams).
Body weight Uterine weight (4 weeks after
OVX)
Week 0 Week 4
OVX/Vehicle 23.6771.92 29.6271.84 0.0370.006**
OVX/E2 24.6772.89 31.1371.73 0.1570.02
Sham/Vehicle 23.4772.21 28.6271.27 0.1470.03
Values are mean 7 SD. *, indicates the signiﬁcant differences at the level of
po0.05.
** Indicates the signiﬁcant differences at the level of po0.01.
Fig. 1. Bone loss and oxidative stress are induced by ovariectomy. (A) Bone density (distal femur and whole body) was determined by DXA immediately prior to surgery and
4 weeks after surgery. Decreased BMD was determined in the OVX/Vehicle group compared to the OVX/E2 and Sham/Vehicle groups (**po0.01). (B) TRAP staining was
performed on sections through the distal femur from OVX and sham-operated animals with/without estrogen replacement to quantify osteoclasts (TRAP positive cells).
(C) Osteoclasts were counted per area (40X) in all groups. Results are expressed as mean þ/ SD. We detected fewer osteoclasts in the OVX/E2 and SHAM groups
(**po0.01) compared to the OVX/Vehicle group. (D) Decreased total GSH (**po0.01) and GSH/GSSG (*po0.05) ratio from bone protein lysates is detected in the OVX/
Vehicle group showing that oxidative stress in OVX mice.
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3.4. Oxidative stress induces PAMM and Nrf2 mRNA expression in
vitro
Ovariectomy causes both estrogen-deﬁciency and oxidative
stress [5]. We observed increased PAMM expression in long bones
of mice from the OVX/Vehicle group suggesting that upregulation
of PAMM was induced by oxidative stress in vivo. To conﬁrm this
observation at the cellular level, we treated human PBMCs with
H2O2 for 20 min, after which we replaced the H2O2-containing
medium with the fresh medium without H2O2 [17,18]. Total RNA
was extracted at 24 h after treatment and analyzed for PAMM
mRNA expression by RT PCR. We found signiﬁcantly increased
PAMM mRNA abundance in human PBMCs treated with 100 mM
H2O2, (Fig. 5A). Nuclear factor-erythroid 2-related factor 2 (Nrf2) is
a transcription factor that regulates the cellular response to oxi-
dative stress by stimulating expression of several antioxidant
proteins [19]. We hypothesized that H2O2-induced PAMM ex-
pression was associated with H2O2-induced Nrf2 mRNA expres-
sion. Indeed, we found a signiﬁcant increase in Nrf2 mRNA in cells
treated with 50 mM H2O2 (Fig. 5B), conﬁrming our hypothesis.
4. Discussion
In this study, we used ovariectomy in mice, a well-established
model system of bone loss induced by estrogen deﬁciency and a
model system of oxidative stress in vivo, to examine the role of
PAMM during pathological bone loss. We also stimulated human
PBMC with hydrogen peroxide (H2O2) to study oxidative stress and
PAMM expression in vitro. We detected increased PAMM abun-
dance in bones from ovariectomized mice 4 weeks after surgery.
We also found increased abundance of PAMM and Nrf2 mRNA in
H2O2-treated cells compared to untreated control cells. We de-
monstrated that blocking estrogen receptor inhibited M-CSF-in-
duced PAMM expression in preosteoclasts. These results suggest
that PAMM may be part of the cellular antioxidant response de-
signed to maintain redox homeostasis.
In previous studies, we showed that PAMM over-expression
prevented the reduction of GSH/GSSG induced by RANKL and
abolished RANKL-induced osteoclast differentiation in RAW 264.7
cells. In human PBMCs, M-CSF induced PAMM expression, while
addition of RANKL resulted in decreased PAMM expression [12].
These ﬁndings indicated that RANKL-induced osteoclast formation
requires down-regulation of PAMM. Hyeon et al. [19] obtained
similar results while studying the role of Nrf2 during osteoclast
differentiation. In fact, RANKL-induced osteoclast differentiation
and bone resorption activity was increased in Nrf2-deﬁcient os-
teoclast-precursors cells compared to wild-type cells. Moreover,
Nrf2 loss resulted in reduced production of several antioxidant
enzymes and glutathione. Importantly, Nrf2 loss (just like PAMM
loss) led to an increase in intracellular ROS level and the oxidized-
to-reduced glutathione ratio. The authors ﬁnally conclude that
Fig. 2. Ovariectomy increases PAMM abundance and Akt phosphorylation in bone. (A) Western blot analysis of protein extracts from distal femur shows increased PAMM
expression and Akt phosphorylation in OVX/Vehicle group (n¼3, lanes 1, 2, and 3) and OVX/E2 group (n¼2, lanes 4 and 5) compared to Sham/Vehicle mice (n¼3, lanes 6, 7,
and 8). (B) PAMM and pAkt are increased in OVX group compare with Sham group (*po0.05). There is a trend toward increased PAMM expression with E2 treatment in OVX
mice. (C) Expression of PAMM at the distal femur was also detected by immunohistochemistry 4 weeks after OVX or Sham-operated mice.
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Nrf2 (alike PAMM) inhibits RANKL-induced osteoclast differ-
entiation by regulating the cellular redox status. This raises the
intriguing idea that PAMM is a novel target of Nrf2, induced by
oxidative stress. Studies aimed at clarifying these connections are
currently under way.
We report in this study that M-CSF stimulation of PAMM ex-
pression requires Akt phosphorylation, via PI3Kinase activity. The
PI3K/Akt signaling pathway is essential for RANKL-RANK mediated
osteoclastic differentiation [20]. This pathway is also known to be
involved in osteoclastogenesis induced by oxidative stress [21]. Akt
is a downstream effector of phosphatidylinositol 3 kinase (PI3K)
and is a critical mediator of cell proliferation and survival in a
variety of cell types [20]. PI3Kinase activity is required for Akt
activation [22,23]. Akt provides a survival signal that protects cells
from apoptosis induced by growth factor withdrawal and oxidative
stress [24]. This pathway involves the activity of PI3P and is,
therefore, wortmannin-sensitive. Akt is activated by phospholipid
at Thr 308 by PDK1 [25] and by phosphorylation within the car-
boxy terminus at Ser473. Activated Akt can, in turn, directly
phosphorylate mTOR in a rapamycin-sensitive way [26,27].
Glantschnig et al. found that M-CSF induced activation of Akt by
phosphorylating residues Thr308 and Ser473 [16].
Our data show that ovarietcomy increases PAMM expression
and suggests a novel mechanistic link between ROS and enhanced
bone resorption. While estrogen replacement blocked both os-
teoclast differentiation and bone loss, it did not block PAMM ex-
pression in bone. This may be indicative of increased numbers of
PAMM-expressing pre-osteoclasts following OVX that do not
terminally differentiate into bone-resorbing osteoclasts due to
estrogen treatment. PAMM was originally identiﬁed as a gene up-
regulated in osteoclasts by both M-CSF and RANKL. We found that
M-CSF alone was able to induce PAMM expression in monocytes
Fig. 3. M-CSF stimulation of PAMM expression requires Akt phosphorylation. Human CD14þ PBMCs were stimulated with M-CSF (þ) and Wortmannin (W) or Rapamycin
(R) for 4 days. M-CSF induced PAMM expression and phosphorylation of Akt (Ser 473). Wortmannin and Rapamycin, on the other hand, blocked M-CSF-induced Akt
phosphorylation and PAMM expression. (): Untreated control cells. (þ): Cells stimulated with 150 ng/mL M-CSF. W: Cells stimulated with M-CSF and 100 nMWortmannin.
R: Cells stimulated with M-CSF and 100 nM Rapamycin.
Fig. 4. Estrogen deﬁciency blocks M-CSF-induced PAMM expression in preosteoclasts. Human CD14þ PBMCs were cultured for 4 days in α-MEM/10% charcoal stripped FBS
supplemented with 150 ng/mL human M-CSF (PeproTech Inc.) (M) and 1 nM E2 (ME2, M-CSFþE2) or with 100 nM ICI 182,780 (ME2I, M-CSFþE2þ ICI). (A) Total RNA was
extracted from the cultured cells and analyzed by qPCR. Real time PCR analysis demonstrates that, compared with the cells treated with M-CSF alone (M), PAMM abundance
is increased in cells treated with M-CSF and Estradiol (ME2), and signiﬁcantly decreased in the presence of ICI 182,780 (ME2I). (B) Western blot analysis from total cell
protein lysates shows that PAMM expression is detected in estrogen-treated cells (ME2). No PAMM band can be observed in ICI 182,782-treated cells (ME2I).
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[12]. Indeed, addition of RANKL resulted in slightly decreased
PAMM expression in cell culture. Estrogen inhibits osteoclast dif-
ferentiation whereas M-CSF/RANKL induces it. However, both sti-
muli enhanced PAMM expression in osteoclast precursors. This
observation suggests that PAMM expression might play a dual role
in osteoclastogenesis: inhibiting osteoclast differentiation while
stimulating proliferation of osteoclast precursors by regulating the
levels of intracellular ROS. Indeed, estrogens have been shown to
negatively regulate the generation of osteoclast precursors [28–
30]. Taken together, our in vivo and in vitro ﬁndings suggest that
estrogen may exert its bone-sparing effect by supporting expres-
sion of PAMM, which prevents osteoclast precursors from differ-
entiating into resorbing osteoclasts.
PAMM is a redox regulatory protein that modulates osteoclast
differentiation in vitro. It can be induced by oxidative stress in vitro
and in vivo. PAMM expression in osteoclasts precursors is stimu-
lated by estrogen. Moreover, estrogen stimulation of PAMM ex-
pression is mediated by phosphorylation of Akt. Our results also
suggest that PAMM is a potential candidate for Akt-mediated
protection against oxidative stress. Therefore, our ﬁndings provide
evidence of a novel mechanism linking cellular redox status and
bone homeotasis and may suggest new approaches to the pre-
vention and/or treatment of human bone diseases by targeting
molecules, like PAMM, that modulate cellular redox status in bone
cells.
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